文献
J-GLOBAL ID:201702258471146454
整理番号:17A1184298
ソラフェニブ治療(RESORCE)上の進行した肝細胞癌患者のためのレゴラフェニブ:無作為化,二重盲検,プラセボ対照,第3相試験【Powered by NICT】
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
著者 (26件):
Bruix Jordi
(Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clinic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, Spain)
,
Qin Shukui
(Chinese People’s Liberation Army Cancer Center of Nanjing Bayi Hospital, Nanjing, China)
,
Merle Philippe
(Groupement Hospitalier Lyon Nord, Hepatology Unit, Lyon, France)
,
Granito Alessandro
(Department of Medical and Surgical Sciences, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy)
,
Huang Yi-Hsiang
(Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan)
,
Bodoky Gyorgy
(St Laszlo Teaching Hospital, Budapest, Hungary)
,
Pracht Marc
(Service d’Oncologie Medicale, Centre Eugene Marquis, Rennes, France)
,
Yokosuka Osamu
(Department of Gastroenterology and Nephrology, Chiba University, Chiba, Japan)
,
Rosmorduc Olivier
(Department of Hepatology, Hopital de la Pitie-Salpetriere, Assistance Publique-Hopitaux de Paris and Universite Pierre et Marie Curie, Sorbonne Universites, Paris, France)
,
Breder Valeriy
(Russian Cancer Research Center n.a.N.Blokhin, Moscow, Russia)
,
Gerolami Rene
(CHU Timone, Universite de la Mediterranee, Marseille, France)
,
Masi Gianluca
(Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy)
,
Ross Paul J
(King’s College Hospital NHS Foundation Trust, London, UK)
,
Song Tianqiang
(Tianjin Medical University Cancer Hospital, Tianjin, China)
,
Bronowicki Jean-Pierre
(INSERM 954, CHU de Nancy, Universite de Lorraine, Nancy, France)
,
Ollivier-Hourmand Isabelle
(Service d’Hepatogastroenterologie, CHU, Caen, France)
,
Kudo Masatoshi
(Kindai University Faculty of Medicine, Osaka, Japan)
,
Cheng Ann-Lii
(Department of Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan)
,
Llovet Josep M
(Barcelona Clinic Liver Cancer (BCLC) Group, Liver Unit, IDIBAPS-Hospital Clinic de Barcelona, CIBERehd, Universitat de Barcelona, Catalonia, Spain)
,
Llovet Josep M
(Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA)
,
Llovet Josep M
(Institucio Catalana de Recerca i Estudis Avancats (ICREA), Barcelona, Spain)
,
Finn Richard S
(Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA)
,
LeBerre Marie-Aude
(Bayer HealthCare SAS, Loos, France)
,
Baumhauer Annette
(Bayer Pharmaceuticals, Bayer Vital GmbH, Leverkusen, Germany)
,
Meinhardt Gerold
(Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA)
,
Han Guohong
(The First Affiliated Hospital (Xijing Hospital) of the Fourth Military Medical University, Xi’an, China)
資料名:
Lancet
(Lancet)
巻:
389
号:
10064
ページ:
56-66
発行年:
2017年
JST資料番号:
B0673A
ISSN:
0140-6736
CODEN:
LANCA
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)